Brief: Senti Biosciences Inc Maintain Expectation Of Cash Runway Into 2024
Nov 10 (Reuters) - Senti Biosciences Inc SNTI.O :
* SENTI BIOSCIENCES INC - CASH POSITION OF $114.9 MILLION
AS OF
SEPTEMBER 30, 2022; MAINTAIN EXPECTATION OF CASH RUNWAY INTO
2024
* SENTI BIOSCIENCES INC - QTRLY NET LOSS WAS $16.6 MILLION,
OR
$0.38 PER BASIC AND DILUTED SHARE
Source text for Eikon: [ID: nNDLvt6Yh]
Further company coverage: SNTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates